TP53 and hepatocellular carcinoma: Furthermore, targeting and downregulating a series of negative regulators of ferroptosis in HCC, such as Nuclear Factor Erythroid 2-related Factor 2 (NRF2), Metallothionein-1G (MT-1G), CDGSH Iron-Sulfur Domain 1 (CISD1), and P53, also offers a feasible approach to accelerate ferroptosis in HCC cells [55].